Vitae Biomedical Co., Ltd. is advancing beyond individual diagnostic products by developing a urine-based testing platform designed to expand access to cancer screening. With lung cancer as its initial focus, the company aims to lower barriers to detection and improve early diagnosis through a more accessible and patient-friendly approach.

Lung cancer remains one of the most challenging diseases globally, with high mortality rates and significant healthcare costs. In Taiwan alone, medical expenditures for lung-related cancers continue to rank among the highest across all disease categories, reflecting both the clinical burden and the limitations of current detection strategies.

Vitae Biomedical’s flagship product, the urine-based lung cancer antigen detection reagent, is positioned within this broader platform to support clinical decision-making. In particular, it assists physicians and patients in managing lung nodules by reducing false positives and minimizing unnecessary invasive procedures.

The platform is especially valuable in regions with limited access to advanced medical infrastructure. By enabling non-invasive, convenient sample collection, it can serve as an initial screening tool as well as a solution for ongoing monitoring, helping extend early detection capabilities to underserved populations.

Driven by a patient-centric philosophy, Vitae Biomedical is committed to developing technologies that reduce both the practical and psychological barriers associated with cancer screening. Through its urine-based platform, the company seeks to encourage broader participation in early detection, ultimately contributing to improved health outcomes.